Guillermo RJJ, Aguilar RJJ, Lazo CCO

Language: Spanish
References: 26
Page: 228-233
PDF size: 54.37 Kb.

ABSTRACT

Objective: To know the frequency of gastrointestinal symptoms between episodes of headache in patients with migraine with aura (MWA) and migraine without aura(MWOA). Methods: It is a cross-sectional, descriptive and observational study obtained by a survey adapted from the criteria of ROME II. An expected percentage of appearance was assigned to to each one of the variables because it is not reported in the medical literature The population of study was obtained from the patients attended in the external consultation of the Regional General Hospital No1 of the IMSS in Merida, Yucatan, Mexico and filled our criteria of inclusion. Our variables are: Pyrosis, abdominal fullness, distension, abdominal pain, constipation and loose tools. An expected percentage of appearance of 0.30 was estimated; the interval of confidence was 0.30 and the level of confidence was 95%. The collected data were processed in the package Microsoft Office Excel 2003 and the simple frequencies and percentages found for each variable were presented in tables. Results: We included 36 patients (30 female and 6 male). 17 patients had MWA) and 19 MWOA. The symptoms were: Pyrosis (80.5%) in 30 patients, 15 MWA and 15 MWOA; Constipation (75%) 27 patients, 14 MWOA and 13 MWA; Abdominal fullness (72.2%) in 26 patients, 13 MWOA and 13 MWA; Distension (69.4%) in 25 patients, 11 MWOA and 14 MWA; Abdominal pain (63.8%) in 23 patients, 13 MWA and 10 MWOA and loose tools (19.4%) in 7 patients, 4 MWOA and 3 MWA. Only 1 (2.7%) patient referred constipation as unique symptom and 1 (2.7%) did not show any symptom. 34 patients had 2 and until the 6 symptoms in combination. Conclusions: There is a similarity in frequency of gastrointestinal symptoms between episodes of headache in patients with both types of migraine, 17 with aura and 18 without aura. 97.2 % had gastrointestinal symptoms probably of functional ethiology.

REFERENCES

1. Millán GRO, Pineda LAG, Pacheco CMF. Migraña. Una Revisión de la Fisiopatogenia y Alternativa Futura. Gac. Med. Méx. (Méx) 2003; 139 (4): 377-80.

2. de la Fuente PJA, de la Fuente RI. Utilidad de un procinético cisaprida en el tratamiento abortivo de la migraña. Arch Neurocien (Mex.) 1997; Vol 2 (1): 29-34.

3. Wolff HG. Headache and other head pain. New York: Oxford University Press. 1963.

4. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 379-90.

5. Graftstein B. Mechanism of spreading cortical depression. J Neurophysiol 1956; 19: 154-71.

6. Moskowitz MA. The Neurobiology of Vascular head pain. Ann Neurol 1984; 16: 157-68.

7. Mendoza CJF. Cefalea en el niño. Martínez MR. Pediatría. La Salud del niño y del adolescente. México, D.F. 4a. edición, Edit El Manual Moderno; 2001, 1097-1101.

8. Headache Classification Committee of the International Headache Society (HIS) Classification and Diagnostic Criteria for Headache Disorders, Cranial, Neuralgias and Facial Pains. Cephalalgia 1988; 8 (suppl 7): 1-96.

9. Blau JN. Classical Migraine symptoms between visual aura and headache onset. The Lancet 1992; 340: 355-56.

10. Bertaccini G. Tissue 5 hydroxytryptamine and urinary 5- hydroxy Indoleacetia and after pontial or total removae of the gastrointestinal tract in the rat. J. Physio (Lond) 1960; 153: 239-49.

11. Sanders-Bush E, Mayer SE. Agonista y antagonista de los receptores de 5-hidroxitriptamina. Goodman & Gilman. Las Bases Farmacológicas de la Terapéutica. 9ª ed. España. Mc Graw Hill Interamericana; 1997: 277-99

12. Gardner LP, Hiatt JL. Histología. Texto y Atlas. 1ª Ed. Philadelphia Pennsylvania, U.S.A., 1997.

13. Gershon M. Review Article: Serotonin Receptor and Transporters Roles in Normal and Abnormal. Gastrointestinal Motility. Aliment Pharm & Therap 2004, Vol. 20 (suppl. 7): 3-14.

14. Sjolund K, Sanden G, Hakanson R, Sundler F. Endocrine Cells in Human Intestine: an Immnocytochemical Study. Gastroenterology 1988; 85: 1120-23.

15. Gershon MD, Kirchgessner AL, Wade PR. Functional anatomy of the enteric nervous system. In Physiology of the gastrointestinal tract. New York: L.R Johnson editors; 1994, 381-422.

16. Espramer V, Testini A. Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 1959; 11: 618-23.

17. Knowles JB, Drossman DA. Evidence Based Gastroenterology and Hepatology. Irritable Bowel Syndrome: Diagnosis and Treatment. BMJ Books (London) 1999; 105: 241-59.

18. Doe YK, Camilleri M. Serotonin: A mediador of the Brain- Gut Connection. Am J Gastroenterol 2000; 95: 2698-709.

19. Gershon. Review article: Roles played by 5- hydroxytryptamine in the Physiology of the bowel. Aliment Pharmacol Ter 1999; 13: 15-30.

20. Gale JD and Bunce, k. T. Pharmacological Characterization of 5-hydroxytryptamine receptor in the gastrointestinal tract. In Serotonin and Gastrointestinal function. Boca Raton Florida USA. TS Gaginella and JJ Galligan Editors; 1996. CRC Press: 33-52.

21. Anuras S. Motility Disorders of the Gastrointestinal Tract: Principles and Practice. New York, Raven Press; 1992.

22. Takeuchi Y. La Migraña y otros Dolores de Cabeza. Fundación Clínica Valle LiLi (online) 1996; 4: Disponible en la Word Wide Web: http://www.clinicalili.org/esp/cartas/ cartas.php?id_carta=4

23. Camilleri M, Ford MJ. Functional Gastrointestinal disease and the autonomic nervous system. A way a head? Gastroenterology 1994; 106: 1114- 18.

24. Rao, SSC. Clinical evaluation of visceral pain. Gastrointestinal motility. Klower Academic/Plenum Publishers (New York) 1999; 265-76.

25. Hulley SB, Cummings SR. Diseño de la investigación Clínica. Un enfoque epidemiológico. Barcelona. Ediciones Doyma, 1993; 236.

26. 26.- Zavala H, Saravia BB. Epidemiología e Impacto Socio Económico de la Migraña. Rev. Neurol. Arg. 2003; 28: 79-84.